Catheter Ablation cuts mortality in heart failure patients with atrial fibrillation

A comprehensive new study published in Pacing and Clinical Electrophysiology has delivered compelling evidence that catheter ablation dramatically improves survival in patients suffering from both heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation — two conditions that, when combined, create a particularly dangerous cardiovascular profile. The research, led by Mohammed Nor of Stamford […]

A comprehensive new study published in Pacing and Clinical Electrophysiology has delivered compelling evidence that catheter ablation dramatically improves survival in patients suffering from both heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation — two conditions that, when combined, create a particularly dangerous cardiovascular profile.

The research, led by Mohammed Nor of Stamford Hospital/Columbia University College of Physicians and Surgeons and co-authored by Olayiwola Bolaji of Memorial Sloan Kettering Cancer Center, analyzed data from 129,486 propensity-matched patients over a three-year follow-up period, making it one of the largest real-world studies to date examining long-term outcomes of catheter ablation in this high-risk population.

The headline finding is striking: patients who underwent catheter ablation experienced a 54% reduction in all-cause mortality compared to those receiving conventional therapy (hazard ratio 0.46; 95% CI: 0.43–0.49; p < 0.001). In a population where survival is often measured in months rather than years, this magnitude of benefit represents a potential paradigm shift in treatment approach.

“These findings build on the foundation established by landmark trials like CASTLE-AF and CABANA,” the authors note, referencing previous randomized controlled trials that first suggested ablation’s superiority over medical management in heart failure patients with atrial fibrillation.

The study also demonstrated significant reductions in all-cause hospitalization (HR 0.94; 95% CI: 0.92–0.95; p < 0.001) and atrial fibrillation recurrence (HR 0.80; 95% CI: 0.79–0.82; p < 0.001) — outcomes that carry substantial implications for patient quality of life and healthcare system resource utilization.

However, the data revealed an important nuance that underscores the complexity of managing these patients: catheter ablation was associated with a modest but statistically significant increase in heart failure hospitalization (HR 1.07; 95% CI: 1.06–1.08; p < 0.001).

This finding may appear counterintuitive given the procedure’s overall survival benefit. Experts suggest several explanations: the procedure itself may temporarily destabilize some patients; ablation recipients, having survived longer, accumulate more time at risk for heart failure events; or the restored sinus rhythm may unmask underlying cardiac dysfunction previously obscured by atrial fibrillation.

“These findings suggest that catheter ablation may provide substantial long-term benefits in this high-risk population,” the authors conclude, “while highlighting the importance of careful patient selection and post-procedural management.”

Heart failure with reduced ejection fraction affects millions worldwide and is characterized by the heart’s inability to pump blood efficiently, with an ejection fraction below 40%. When atrial fibrillation — the most common sustained cardiac arrhythmia — complicates this condition, patients face a particularly grim prognosis. The irregular, often rapid heart rhythm disrupts the heart’s already compromised pumping action, accelerates disease progression, and substantially increases the risk of stroke, hospitalization, and death.

Catheter ablation works by using radiofrequency energy or cryotherapy to create precise lesions in heart tissue, electrically isolating the pulmonary veins where most atrial fibrillation triggers originate. By eliminating or reducing arrhythmia burden, the procedure allows the heart to function more efficiently, potentially enabling reverse remodeling of the damaged ventricle.

This real-world evidence complements findings from several pivotal randomized trials. The CASTLE-AF trial, published in the New England Journal of Medicine in 2018, demonstrated that catheter ablation significantly reduced death and heart failure hospitalization in patients with HFrEF and atrial fibrillation. More recently, the CASTLE-HTx trial extended these findings to patients with end-stage heart failure, showing that even the sickest patients can derive meaningful benefit.

A 2024 meta-analysis published in JAMA Cardiology synthesized evidence from 12 randomized controlled trials, confirming that catheter ablation reduces heart failure events and mortality in HFrEF patients but shows limited benefit in those with preserved ejection fraction — a critical distinction for clinical practice.

The current study’s strength lies in its massive sample size and real-world applicability. By utilizing the TriNetX US Collaborative Network — a federated database encompassing electronic health records from healthcare organizations nationwide — the researchers captured outcomes from diverse clinical settings, enhancing the generalizability of their findings beyond the controlled environments of randomized trials.

The evidence supporting catheter ablation in HFrEF patients with atrial fibrillation has now reached a level where current guidelines, including those from the European Society of Cardiology, recommend the procedure as a treatment option for appropriately selected patients. This study reinforces those recommendations while providing clinicians with robust data to inform shared decision-making conversations.

Patient selection remains paramount. The authors emphasize that not all patients derive equal benefit, and factors including baseline ventricular function, atrial fibrillation duration, and comorbidity burden influence outcomes. The finding of increased heart failure hospitalizations, while not negating the overall survival advantage, suggests that ablation centers must maintain robust post-procedural monitoring and heart failure management protocols.

For the estimated 6 million Americans living with heart failure and the millions more with atrial fibrillation — conditions whose prevalence is rising with an aging population — these findings offer renewed hope. A procedure once reserved primarily for symptom control has now demonstrated the ability to alter the trajectory of disease and extend life.